Preliminary results from the late-stage human trial of Russia’s main coronavirus vaccine candidate could include data from 5,000-10,000 participants, Denis Logunov, a director at the Gamaleya Institute that developed the vaccine, said on Monday. Russia’s plan to publish preliminary data about the Sputnik V jab as early as November is likely to make it one of the first vaccine developers to share any data from a final stage trial, known as Phase III, but also puts it at odds with competitors. Interim results, when published, will be based on the first 42 days of monitoring participants, Gamaleya developers told Reuters last month.
